Neuronetics, Inc.: financial statements

STIMNASDAQHealthcare · Surgical & Medical Instruments & Apparatus

Price

$1.24

November 19, 2026Market cap $96M

What Ploutos Investor adds for Neuronetics

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 10 fiscal years, from 2016
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The share price has fallen 52% since Nov 4, 2026, when the 10-Q these figures come from was filed ($2.71 then, $1.29 on Nov 19, 2026). The figures date from before that move.10-Q
  • The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.

Financial statements

Each fiscal year's income statement, balance sheet and cash flow as the company filed them, and the latest quarters.

2023–2025 fiscal years

Click a line to see it on the chart.

Revenue

+44.6% a year over 2 years

Line202320242025Average a year
Revenue $71M$75M$149M+44.6%
Cost of revenue $20M$21M$77M+97.7%
Gross profit $52M$54M$72M+18.2%
Operating income -$31M-$35M-$31M
Net income -$30M-$44M-$39M
Earnings per share -$1.05-$1.38-$0.59
Earnings per share, basic -$1.05-$1.38-$0.59
Margins
Gross margin 72.5%72.3%48.5%
Operating margin -42.8%-46.2%-21.1%
Net margin -42.3%-58.4%-26.1%

Financial statements

STIM's revenue, profits and cash flows from 2016 to 2022, 7 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

By segment

Revenue and operating income by business segment or by product, as the company itself reports them in each year's 10-K. Each year from the latest filing that carries it, so a segment renamed or re-cut shows in its current form.

  • 2024: Clinical Services $4.4M, Medical Device $70M
  • 2025: Clinical Services $87M, Medical Device $62M
Segment20242025Share 2025
Clinical Services$4.4M$87M58%
Medical Device$70M$62M42%

From the XBRL of 8 of the company's annual reports to the SEC (ASC 280). Amounts in dollars.

Amounts are in dollars as the company filed them in its annual reports (10-K or 20-F). Those reporting in another currency are converted at each fiscal year-end rate. Shares and earnings per share are adjusted for splits.

Debt and obligations

What the company owes beyond the loans on its balance sheet, and when it pays, from the notes to its annual report: debt maturities, leases, pension plans, goodwill by segment, and how it gets to the tax it pays.

$0 Due within 2 years$24M Leases

The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.

When the debt falls due

Dec 31, 2025

Due within 2 years

$0

Principal of loans and bonds falling due, from the annual report dated December 31, 2025, without leases and interest. The filing

  • 2026: –
  • 2027: –

Leases

Dec 31, 2025

Operating leases

$24M

Finance leases

–

The liability is the present value of the rent still to pay, at December 31, 2025. It is not counted in the ladder's debt. The filing

Goodwill by segment

Dec 31, 2025

Total goodwill

$24M

The company does not state its goodwill by segment, at December 31, 2025. The filing

Claims ahead of shareholders

What stands between the business and its shareholders besides the debt, and the financial assets on the other side, from the latest balance sheet.

$3.7M ahead of the shares3.8% of market value

$3.7M of other claims rank ahead of the shares, about 3.8% of the market value.

Ahead of the shares

at Sep 30, 2026
$3.7M

From the balance sheet of September 30, 2026. The retirement and environmental lines and the pension deficit come from the latest annual report when the quarter's filing does not state them, each with its own date. Market value at the price of November 19, 2026. A line is listed when it is at least 0.5% of the market value. A description of the balance sheet, not a valuation.

Earnings quality

How the reported earnings were made, read from the filings. A description, not a score: our tests found no link between these measures and later share returns.

Receivables and inventory against sales

In the quarter to Sep 30, 2026, sales were +12.5% on the same quarter a year earlier, and receivables -22.8%. Inventory was +14.4%, against -0.6% for the cost of sales.

a year earlier 46 days
31 days
a year earlier 20 days
22 days

Balances at Sep 30, 2026 and Sep 30, 2025, against the sales and cost of sales of the quarter ending on each date; a fourth quarter is the fiscal year less its first nine months. Same quarter against same quarter, so the season is the same.

Allowance for doubtful accounts

The allowance for receivables that may not be collected was 3.8% of gross receivables at Sep 30, 2026, against 5.4% a year earlier.

At last year's share it would be $245.4K larger. A smaller allowance means a smaller charge for bad debts in profit.

  • The share fell more than at nine in ten S&P 500 companies that report it.
a year earlier $1.1M
$563.0K

The earnings per share split is not shown: a figure it needs is missing from the company's structured filings.

The tax part is not shown: a figure it needs is missing from the company's structured filings.

A reading is called out when it is above the 90th percentile of the same reading across the S&P 500, or, for a fall, below the 10th, as measured on 9 November 2026. Each part uses only the company's own filings.

The full analysis

What do Neuronetics's filings show?

These are Neuronetics's figures from its filings. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about STIM's financials

Didn't find what you were looking for?

Ask us
How much revenue did STIM have in 2025?

Neuronetics had revenue of $149M and net income of -$39M in fiscal 2025, a net margin of -26.1%.

How much debt does STIM have?

On December 31, 2025 Neuronetics had total assets of $142M, debt of $66M and shareholders' equity of $22M.

How much free cash flow does STIM have?

In fiscal 2025 Neuronetics had cash from operations of -$20M and spent $801.0K on capital expenditure, leaving -$21M of free cash flow.

Where are the figures from?

From Neuronetics, Inc.'s annual and quarterly reports to the SEC, read from the structured data (XBRL) it files itself.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.